Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NovaCardia Inc.

Division of Merck & Co. Inc.

Latest From NovaCardia Inc.

Early Stage Investing is Name of Game for Versant

Versant Ventures wrapped up $500 million for a new venture fund, an achievement based chiefly on its prowess as an early stage investor.

Biopharma VC Exits 2005-2007: Cheap IPOs, Expensive Acquisitions

Over the past three years, acquisitions have outperformed IPOs in terms of step-ups and total value. Here we take a look at the average valuations each year for the two exit categories. The figures suggest that although IPO is the logical exit, in most cases investors will advocate exploring M&A almost all of the time as well.
BioPharmaceutical Business Strategies

The A-List: 2007's Trend Shaping Series A Financings

In 2007, what did Series A venture investments reveal about the state of the health care industry? It was very healthy, thank you. There were quite a few deals to choose from, and numbers demonstrated continued growth in diagnostics fundraising, a resurgence in vaccines, and evidence of pharma's interest in proof-of-concept projects and large-molecule platforms. Medical device investors, meanwhile, remain enamored with concept companies seeking to blend electronics-such as neurostimulation or miniature sensors-with devices.
BioPharmaceutical Medical Device

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2007

In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for July-September 2007. Our data come from Windhover's Strategic Transactions Database.
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Randall Woods, Pres. & CEO
    John E Crawford , CFO
    Howard C Dittrich, MD, CMO
  • Contact Info
  • NovaCardia Inc.
    Phone: (858) 509-0455
    12750 High Bluff Dr.
    Ste. 300
    San Diego, CA 92130